Z8526711350 (also known as '1350 or YVF) is a synthetic cannabinoid from the pyrazolecarboxamide family. It was developed using an ultra-large-scale docking approach to screen a library of 12 billion molecules and then dock 74 million of these against an in silico model of the CB1 receptor, of which the most promising 60 hits were prioritised for synthesis. 46 molecules were successfully made, of which 9 proved to show significant affinity to CB1 and two of these were found to be active as CB1 agonists with suitable solubility properties for further testing. Of these, ZINC537551486 was found to have a binding affinity of 731 nM at CB1 and was selected for further synthetic elaboration. After two rounds of synthetic modification for increased potency, the active enantiomer Z8526711350 was found to have a CB1 affinity of 0.95 nM, which made it stronger than the reference agonist CP 55,940 used for the docking studies. Z8526711350 was found to be a potent analgesic in animal models and also showed efficacy against allodynia caused by nerve damage, suggesting potential applications for the treatment of neuropathic pain. However, it is also believed to show functional selectivity as it showed reduced levels of sedation and of other animal surrogates of psychoactive effects.
See also 5F-AB-FUPPYCA Tedalinab Z3517967757 Z0443438219
References


